Preview

Кардиоваскулярная терапия и профилактика

Расширенный поиск

Безопасность и эффективность сульфгидрильного ингибитора ангиотензин-превращающего фермента зофеноприла в лечении сердечно-сосудистых заболеваний

https://doi.org/10.15829/1728-8800-2011-6-99-104

Полный текст:

Аннотация

Начиная с 1970-х гг., медикаментозная терапия, подавляющая влияние ренин-ангиотензин-альдостероновой системы (РААС), рассматривалась в качестве эффективного метода лечения больных с высокорениновой гипертензией (АГ). Позднее было показано, что ингибиторы ангиотензин-превращающего фермента (ИАПФ) эффективны не только у пациентов с высокими уровнями ренина и артериального давления (АД), но и у значительной части больных АГ и нормальными значениями активности ренина плазмы (АРП). ИАПФ применяются для лечения целого ряда хронических заболеваний, таких как атеросклероз, АГ, инфаркт миокарда (ИМ), сердечная недостаточность, осложнения сахарного диабета и инсульт. В настоящее время выполнено более 90 контролируемых, клинических исследований по оценке благоприятных терапевтических эффектов 14 различных молекул ИАПФ. Согласно данным экспериментальных исследований, ИАПФ способны замедлять развитие атеросклероза, уменьшать выраженность окислительного стресса (ОС) и сосудистого воспаления у лабораторных животных различных видов. Это свидетельствует о том, что ИАПФ оказывают благоприятное действие на состояние кровеносных сосудов. Более 15 лет назад сульфгидрильный ИАПФ зофеноприл продемонстрировал отличную клиническую эффективность и безопасность у пациентов с АГ и больных ИМ. Не так давно были выявлены выраженные антиокислительное и антиатеросклеротическое действия этого препарата, что свидетельствует о наличии клинически значимого вазопротективного эффекта.

Об авторе

К. Наполи
Отделение общей патологии, научно-исследовательский центр клинической патологии сердечнососудистых заболеваний, 1-я Школа медицины, Университет Неаполя
Италия


Список литературы

1. Heeneman S, Sluimer JC, Daemen MJ. Angiotensin-converting enzyme and vascular remodeling. Circ Res 2007; 101: 441-54.

2. Napoli C, Loscalzo J. New challenges for ACE-inhibitors in vascular diseases. Drug Design Rev 2005; 2:485-93.

3. Napoli C, Sica V, Pignalosa O, de Nigris F. New trends in antiatherosclerotic agents. Curr Med Chem 2005; 12: 1755-72.

4. Napoli C, de Nigris F, Williams-Ignarro S, et al. Nitric oxide and atherosclerosis: An update. Nitric Oxide 2006; 15: 265-79.

5. Jacoby DS, Rader DJ. Renin-angiotensin system and atherothrombotic disease: from genes to treatment. Arch Intern Med 2003; 26; 163: 1155-64.

6. Fyhrquist F, Saijonmaa O. Renin-angiotensin system revisited. J Intern Med 2008; 264: 224-36.

7. Unger T. the role of the renin-angiotensin system in the development of cardiovascular disease. Am J Cardiol 2002; 89: 3A-10.

8. Scribner AW, Loscalzo J, Napoli C. The effect of angiotensinconverting enzyme inhibition on endothelial function and oxidant stress. Eur J Pharmacol 2003; 482(1-3): 95-9.

9. Cominacini L, Pasini A, Garbin U, et al. Zofenopril inhibits the expression of adhesion molecules on endothelial cells by reducing reactive oxygen species. Am J Hypertens 2002; 15(10 Pt 1): 891-5.

10. Napoli C, Cicala C, D’Armiento FP, et al. Beneficial effects of ACEinhibition with zofenopril on plaque formation and lowdensity lipoprotein oxidation in watanabe heritable hyperlipidemic rabbits. Gen Pharmacol 1999; 33: 467-77.

11. de Nigris F, D’Armiento FP, Somma P, et al. Chronic treatment with sulfhydryl angiotensin-converting enzyme inhibitors reduce susceptibility of plasma LDL to in vitro oxidation, formation of oxidation-specific epitopes in the arterial wall, and atherogenesis in apolipoprotein E knockout mice. Int J Cardiol 2001; 81: 107-15.

12. Frascarelli S, Ghelardoni S, Ronca-Testoni S, Zucchi R. Cardioprotective effect of zofenopril in perfused rat heart subjected to ischemia and reperfusion. J Cardiovasc Pharmacol 2004; 43: 294-9.

13. Westendorp B, Schoemaker RG, Buikema H, et al. Dietary sodium restriction specifically potentiates left ventricular ACE inhibition by zofenopril, and is associated with attenuated hypertrophic response in rats with myocardial infarction. J Ren Angioten Aldoster Syst 2004; 5: 27-32.

14. Bucci M, Roviezzo F, Brancaleone V, et al. ACE-inhibition ameliorates vascular reactivity and delays diabetes outcome in NOD mice. Vascul Pharmacol 2008; 49: 84-90.

15. Altunoluk B, Soylemez H, Oguz F, et al. An Angiotensinconverting enzyme inhibitor, zofenopril, prevents renal ischemia/reperfusion injury in rats. Ann Clin Lab Sci 2006; 36: 326-32.

16. Riccioni G. The Effect of Antihypertensive Drugs on Carotid Intima Media Thickness: An Up-to-Date Review. Curr Med Chem 2009; 16: 988-96.

17. O’Keefe JH, Wetzel M, Moe RR, et al. Should an angiotensinconverting enzyme inhibitor be standard therapy for patients with atherosclerotic disease? JACC 2001; 37: 1-8.

18. Re RN. Mechanisms of disease: local renin-angiotensin-aldosterone systems and the pathogenesis and treatment of cardiovascular disease. Nat Clin Pract Cardiovasc Med 2004; 1: 42-7.

19. Schmieder RE, Hilgers KF, Schlaich MP, Schmidt BM. Reninangiotensin system and cardiovascular risk. Lancet 2007; 369: 1208-19.

20. Yusuf S, Pepine CJ, Garces C, et al. Effect of enalapril on myocardial infarction and unstable angina in patients with low ejection fractions. Lancet 1992; 340: 1173-8.

21. Pfeffer MA, Braunwald E, Moye LA, et al. Effect of captopril on mortality and morbidity in patients with left ventricular dysfunction after myocardial infarction: Results of the survival and ventricular enlargement trial. The SAVE Investigators. N Engl J Med 1992; 327: 669-77.

22. Cleland JG, Erhardt L, Murray G, et al. Effect of ramipril on morbidity and mode of death among survivors of acute myocardial infarction with clinical evidence of heart failure: A report from the AIRE Study Investigators. Eur Heart J 1997; 18: 14-5.

23. Kober L, Torp-Pedersen C, Carlsen JE, et al. A clinical trial of the angiotensin-converting-enzyme inhibitor trandolapril in patients with left ventricular dysfunction after myocardial infarction: Trandolapril Cardiac Evaluation (TRACE) study group. N Engl J Med. 1995; 333: 1670-6.

24. Flather MD, Yusuf S, Kober L, et al. Long-term ACE-inhibitor therapy in patients with heart failure or left-ventricular dysfunction: a systematic overview of data from individual patients. ACEInhibitor Myocardial Infarction Collaborative Group. Lancet 2000; 355: 1575-81.

25. Domanski MJ, Exner DV, Borkowf CB, et al. Effect of angiotensin converting enzyme inhibition on sudden cardiac death in patients following acute myocardial infarction: A meta-analysis of randomized clinical trials. JACC 1999; 33: 598-604.

26. MacMahon S, Sharpe N, Gamble G, et al. Randomized, placebo-controlled trial of the angiotensin-converting enzyme inhibitor, ramipril, in patients with coronary or other occlusive arterial disease: PART-2 Collaborative Research Group. Prevention of Atherosclerosis with Ramipril. JACC 2000; 36: 438-43.

27. Teo KK, Burton JR, Buller CE, et al. Long-term effects of cholesterol lowering, and angiotensin-converting enzyme inhibition on coronary atherosclerosis: the Simvastatin/Enalapril coronary atherosclerosis trial. Circulation 2000; 102: 1748-54.

28. Lonn EM, Yusuf S, Dzavik V, et al. Effects of ramipril and vitamin E on atherosclerosis: the Study to Evaluate Carotid Ultrasound Changes in Patients Treated with Ramipril and Vitamin E (SECURE). Circulation 2001; 103: 919-25.

29. The Heart Outcomes Prevention Evaluation Study Investigators, Effects of an angiotensin-converting-enzyme inhibitor ramipril, on cardiovascular events in high-risk patients. N Engl J Med 2000; 342: 145-53.

30. Ambrosioni E. Defining the role of zofenopril in the management of hypertension and ischemic heart disorders. Am J Cardiovasc Drugs 2007; 7: 17-24.

31. Matarrese M, Salimbeni A, Turolla EA, et al. 11C-Radiosynthesis and preliminary human evaluation of the disposition of the ACE inhibitor [11C] zofenoprilat. Bioorg Med Chem 2004; 12: 603-11.

32. Ambrosioni E, Borghi C, Magnani B. The effect of angiotensinconvertingenzyme inhibitor zofenopril on mortality and morbidity after anterior myocardial infarction. N Engl J Med 1995; 332: 80-5.

33. Borghi C, Bacchelli S, Esposti DD, et al. Effects of the administration of an angiotensinconverting enzyme inhibitor during the acute phase of myocardial infarction in patients with arterial hypertension. SMILE Study Investigators. Survival of Myocardial Infarction Long-term Evaluation. Am J Hypertens 1999; 12: 665-72.

34. Borghi C, Ambrosioni E. Double-blind comparison between zofenopril and lisinopril in patients with acute myocardial infarction: Results of the Survival of Myocardial Infarction Long-Term Evaluation-2 (SMILE-2) study. Am Heart J 2003; 145: 80-7.

35. Borghi C, Ambrosioni E; Survival of Myocardial Infarction Long-term Evaluation Study Group. Effects of zofenopril on myocardial ischemia in post-myocardial infarction patients with preserved left ventricular function: the Survival of Myocardial Infarction Long-term Evaluation (SMILE)-ISCHEMIA study. Am Heart J 2007; 153(3): 445: e7-14.

36. Borghi C, Cicero AF. Ambrosioni E. Effects of early treatment with zofenopril in patients with myocardial infarction and metabolic syndrome: the SMILE Study. Vasc Health Risk Manag 2008; 4: 665-71.

37. Malacco E, Omboni S. Antihypertensive efficacy of zofenopril plus hydrochlorothiazide fixed combination for treatment in metabolic syndrome. Adv Ther 2007; 24: 1006-15.

38. Mallion JM. An evaluation of the initial and long-term antihypertensive efficacy of zofenopril compared with enalapril in mild to moderate hypertension. Blood Press Suppl 2007; 2: 13-8.

39. Nilsson P. Antihypertensive efficacy of zofenopril compared with atenolol in patients with mild to moderate hypertension. Blood Press Suppl 2007; 2: 25-30.

40. Farsang C. Blood pressure control and response rates with zofenopril compared with amlodipine in hypertensive patients. Blood Press Suppl 2007; 2: 19-24.

41. Narkiewicz K. Comparison of home and office blood pressure in hypertensive patients treated with zofenopril or losartan. Blood Press Suppl 2007; 2: 7-12.

42. Malacco E, Piazza S, Omboni S; on behalf of the Zofenopril Study Group. Zofenopril versus Lisinopril in the Treatment of Essential Hypertension in Elderly Patients: A Randomised, Double-Blind, Multicentre Study. Clin Drug Investig 2005; 25(3): 175-82.

43. Napoli C, Sica V, de Nigris F, et al. Sulfhydryl angiotensinconverting enzyme inhibition induces sustained reduction of systemic oxidative stress and improves the nitric oxide pathway in patients with essential hypertension. Am Heart J 2004; 148: e5-12.

44. Napoli C, Bruzzese G, Ignarro LJ, et al. Long-term treatment with sulfhydryl angiotensin-converting enzyme inhibition reduces carotid intima-media thickening and improves the nitric oxide/oxidative stress pathways in newly diagnosed patients with mild to moderate primary hypertension. Am Heart J 2008; 156: e1154-8.

45. Pasini AF, Garbin U, Nava MC, et al. Effect of sulfhydryl and non-sulfhydryl angiotensin-converting enzyme inhibitors on endothelial function in essential hypertensive patients. Am J Hypertens 2007; 20: 443-50.

46. Napoli C, Ignarro LJ. Polymorphisms in endothelial nitric oxide synthase and carotid artery atherosclerosis. J Clin Pathol 2007; 60: 341-4.

47. Anderson TJ, Elstein E, Haber H, Charbonneau F. Comparative study of ACE-inhibition, angiotensin II antagonism, and calcium channel blockade on flow-mediated vasodilation in patients with coronary disease. JACC 2000; 35: 60-6.

48. Prasad A, Narayanan S, Husain S, et al. Insertion-deletion polymorphism of the ACE gene modulates reversibility of endothelial dysfunction with ACE inhibition. Circulation 2000; 102: 35-41.

49. Napoli C, Lerman LO, de Nigris F, et al. Rethinking primary prevention of atherosclerosis-related diseases. Circulation 2006; 114: 2517-27.

50. Napoli C, Cacciatore F. Novel pathogenic insights in the primary prevention of cardiovascular disease. Prog Cardiovasc Dis 2009; 51: 503-23.


Для цитирования:


Наполи К. Безопасность и эффективность сульфгидрильного ингибитора ангиотензин-превращающего фермента зофеноприла в лечении сердечно-сосудистых заболеваний. Кардиоваскулярная терапия и профилактика. 2011;10(6):99-104. https://doi.org/10.15829/1728-8800-2011-6-99-104

For citation:


Napoli C. Safety and efficacy of the sulfydryl ACE-inhibitor zofenopril in the management of cardiovascular disease. Cardiovascular Therapy and Prevention. 2011;10(6):99-104. (In Russ.) https://doi.org/10.15829/1728-8800-2011-6-99-104

Просмотров: 42


Creative Commons License
Контент доступен под лицензией Creative Commons Attribution 4.0 License.


ISSN 1728-8800 (Print)
ISSN 2619-0125 (Online)